EHA 2022 | Updates from the MURANO trial
Arnon Kater
• 9 Jun 2022
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, gives an update on the MURANO study (NCT02005471). MURANO was the first study to investigate fixed-duration venetoclax plus rituximab compared with bendamustine and rituximab in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Prof. Kater notes that many publications and presentations have come from this study – including a deep dive into measurable residual disease (MRD) and its use as a surrogate endpoint, as well as reports on mechanisms of resistance and re-treating patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
